Pamela Wolters
0000-0001-9319-6281
National Cancer Institute
2 papers found
Refreshing results…
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Missing publications? Search for publications with a matching author name.